Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (61-70 of 282) with videos related to

Pageof 29
Sort By:
Cancer|February 14, 2015
Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Susan Halabi, Brian I Rini, Bernard Escudier, et al.
BJU International|October 10, 2007
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102George K Philips, Susan Halabi, Ben L Sanford, et al.
Urologic Oncology|October 7, 2004
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901Asim Amin, Susan Halabi, Edward P Gelmann, et al.
European Urology Focus|February 5, 2019
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate CancerJayne F Tierney, Claire L Vale, Wendy R Parelukar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583Susan Halabi, Eric J Small, Daniel F Hayes, et al.
The Journal of Urology|June 7, 2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Clinical Trials (London, England)|September 4, 2016
Comparison of futility monitoring guidelines using completed phase III oncology trialsQiang Zhang, Boris Freidlin, Edward L Korn, et al.
Clinical Trials (London, England)|April 4, 2024
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project OptimusPeter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, et al.
Urologic Oncology|January 18, 2015
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancerRhonda L Bitting, Patrick Healy, Susan Halabi, et al.
Epidemiology (Cambridge, Mass.)|December 17, 2005
Analgesic drug use and risk of ovarian cancerJoellen M Schildkraut, Patricia G Moorman, Susan Halabi, et al.
Pageof 29

Showing results (61-70 of 282) with videos related to

Sort By:
Pageof 29
Cancer|February 14, 2015
Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint?Susan Halabi, Brian I Rini, Bernard Escudier, et al.
BJU International|October 10, 2007
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102George K Philips, Susan Halabi, Ben L Sanford, et al.
Urologic Oncology|October 7, 2004
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901Asim Amin, Susan Halabi, Edward P Gelmann, et al.
European Urology Focus|February 5, 2019
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate CancerJayne F Tierney, Claire L Vale, Wendy R Parelukar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583Susan Halabi, Eric J Small, Daniel F Hayes, et al.
The Journal of Urology|June 7, 2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Clinical Trials (London, England)|September 4, 2016
Comparison of futility monitoring guidelines using completed phase III oncology trialsQiang Zhang, Boris Freidlin, Edward L Korn, et al.
Clinical Trials (London, England)|April 4, 2024
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project OptimusPeter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, et al.
Urologic Oncology|January 18, 2015
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancerRhonda L Bitting, Patrick Healy, Susan Halabi, et al.
Epidemiology (Cambridge, Mass.)|December 17, 2005
Analgesic drug use and risk of ovarian cancerJoellen M Schildkraut, Patricia G Moorman, Susan Halabi, et al.
Pageof 29